PMC:7121452 / 1167-1790 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"47","span":{"begin":24,"end":27},"obj":"Gene"},{"id":"48","span":{"begin":318,"end":322},"obj":"Gene"},{"id":"49","span":{"begin":400,"end":404},"obj":"Gene"},{"id":"50","span":{"begin":97,"end":105},"obj":"Species"},{"id":"51","span":{"begin":176,"end":182},"obj":"Species"},{"id":"52","span":{"begin":346,"end":352},"obj":"Species"},{"id":"53","span":{"begin":446,"end":454},"obj":"Species"},{"id":"54","span":{"begin":581,"end":589},"obj":"Species"},{"id":"55","span":{"begin":111,"end":119},"obj":"Disease"},{"id":"56","span":{"begin":460,"end":471},"obj":"Disease"},{"id":"57","span":{"begin":614,"end":622},"obj":"Disease"}],"attributes":[{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"Gene:1636"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Gene:59272"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Gene:59272"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Tax:9606"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Tax:9606"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:9606"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:9606"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"Tax:9606"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:C000657245"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:D055370"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Given the common use of ACE inhibitors and ARBs worldwide, guidance on the use of these drugs in patients with Covid-19 is urgently needed. Here, we highlight that the data in humans are too limited to support or refute these hypotheses and concerns. Specifically, we discuss the uncertain effects of RAAS blockers on ACE2 levels and activity in humans, and we propose an alternative hypothesis that ACE2 may be beneficial rather than harmful in patients with lung injury. We also explicitly raise the concern that withdrawal of RAAS inhibitors may be harmful in certain high-risk patients with known or suspected Covid-19."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":460,"end":464},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Given the common use of ACE inhibitors and ARBs worldwide, guidance on the use of these drugs in patients with Covid-19 is urgently needed. Here, we highlight that the data in humans are too limited to support or refute these hypotheses and concerns. Specifically, we discuss the uncertain effects of RAAS blockers on ACE2 levels and activity in humans, and we propose an alternative hypothesis that ACE2 may be beneficial rather than harmful in patients with lung injury. We also explicitly raise the concern that withdrawal of RAAS inhibitors may be harmful in certain high-risk patients with known or suspected Covid-19."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":460,"end":464},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Given the common use of ACE inhibitors and ARBs worldwide, guidance on the use of these drugs in patients with Covid-19 is urgently needed. Here, we highlight that the data in humans are too limited to support or refute these hypotheses and concerns. Specifically, we discuss the uncertain effects of RAAS blockers on ACE2 levels and activity in humans, and we propose an alternative hypothesis that ACE2 may be beneficial rather than harmful in patients with lung injury. We also explicitly raise the concern that withdrawal of RAAS inhibitors may be harmful in certain high-risk patients with known or suspected Covid-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T8","span":{"begin":465,"end":471},"obj":"Disease"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"}],"text":"Given the common use of ACE inhibitors and ARBs worldwide, guidance on the use of these drugs in patients with Covid-19 is urgently needed. Here, we highlight that the data in humans are too limited to support or refute these hypotheses and concerns. Specifically, we discuss the uncertain effects of RAAS blockers on ACE2 levels and activity in humans, and we propose an alternative hypothesis that ACE2 may be beneficial rather than harmful in patients with lung injury. We also explicitly raise the concern that withdrawal of RAAS inhibitors may be harmful in certain high-risk patients with known or suspected Covid-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":176,"end":182},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T10","span":{"begin":334,"end":342},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T11","span":{"begin":346,"end":352},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T12","span":{"begin":460,"end":464},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T13","span":{"begin":460,"end":464},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"Given the common use of ACE inhibitors and ARBs worldwide, guidance on the use of these drugs in patients with Covid-19 is urgently needed. Here, we highlight that the data in humans are too limited to support or refute these hypotheses and concerns. Specifically, we discuss the uncertain effects of RAAS blockers on ACE2 levels and activity in humans, and we propose an alternative hypothesis that ACE2 may be beneficial rather than harmful in patients with lung injury. We also explicitly raise the concern that withdrawal of RAAS inhibitors may be harmful in certain high-risk patients with known or suspected Covid-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T12","span":{"begin":24,"end":38},"obj":"Chemical"},{"id":"T13","span":{"begin":28,"end":38},"obj":"Chemical"},{"id":"T14","span":{"begin":88,"end":93},"obj":"Chemical"},{"id":"T15","span":{"begin":534,"end":544},"obj":"Chemical"}],"attributes":[{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"Given the common use of ACE inhibitors and ARBs worldwide, guidance on the use of these drugs in patients with Covid-19 is urgently needed. Here, we highlight that the data in humans are too limited to support or refute these hypotheses and concerns. Specifically, we discuss the uncertain effects of RAAS blockers on ACE2 levels and activity in humans, and we propose an alternative hypothesis that ACE2 may be beneficial rather than harmful in patients with lung injury. We also explicitly raise the concern that withdrawal of RAAS inhibitors may be harmful in certain high-risk patients with known or suspected Covid-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":0,"end":139},"obj":"Sentence"},{"id":"T5","span":{"begin":140,"end":250},"obj":"Sentence"},{"id":"T6","span":{"begin":251,"end":472},"obj":"Sentence"},{"id":"T7","span":{"begin":473,"end":623},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Given the common use of ACE inhibitors and ARBs worldwide, guidance on the use of these drugs in patients with Covid-19 is urgently needed. Here, we highlight that the data in humans are too limited to support or refute these hypotheses and concerns. Specifically, we discuss the uncertain effects of RAAS blockers on ACE2 levels and activity in humans, and we propose an alternative hypothesis that ACE2 may be beneficial rather than harmful in patients with lung injury. We also explicitly raise the concern that withdrawal of RAAS inhibitors may be harmful in certain high-risk patients with known or suspected Covid-19."}